Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. (NY: OGN )

20.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co.

< Previous 1 2 3 4 5 6 7 8 9 Next >
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
3 Cheap High Dividend Stocks For Passive Income
These undervalued high yield stocks could return over 10% per year. 
Via Talk Markets
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
High Dividend 50: Organon & Co.
Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%. 
Via Talk Markets
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks." 
Via Benzinga
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
These exchange-traded funds should keep the income flowing in regularly. 
Via The Motley Fool
Topics ETFs
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence. 
Via InvestorPlace
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Organon Beats On Q1, Women's Health Leads the Charge
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared. 
Via Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing. 
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. 
Via InvestorPlace
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals. 
Via InvestorPlace
5 Value Stocks In The Healthcare Sector
Via Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday. 
Via Investor's Business Daily
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion. 
Via InvestorPlace
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast).  
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.